Article

891 views
Yescarta is the US FDA approved CAR T-cell based gene therapy developed by Kite Pharma for the treatment of a deadly form of blood cancer. Here are the 8 interesting facts that you should know about the FDA approved, second “living therapy.” Continue reading...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

KEY POINTS Yescarta is the US FDA approved second CAR T-cell based gene therapy. Here are the 8 interesting facts ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in NEW DRUG APPROVAL


BRIEFING

FDA Approves Glatopa, Generic Version of Teva’s Top-Selling Multiple Sclerosis Drug Copaxone

US FDA approved Glatopa®, generic version of Teva’s Copaxone developed by Sandoz (Novartis’ biosimilar division) in collaboration with Momenta Pharma. Continue reading...

BRIEFING

FDA Approves Vertex Pharma’s Third Cystic Fibrosis Drug Symdeco

Vertex Pharma’s third cystic fibrosis drug, Symdeco™ received the US FDA approval for treating the underlying causes of cystic fibrosis in children aged 12 years and older, having two copies of the F508del mutation or one mutation that is responsive to Symdeco. Continue reading...

NEW DRUG APPROVAL

8 Interesting Facts About FDA Approved, Second Cancer Gene Therapy

Yescarta is the US FDA approved CAR T-cell based gene therapy developed by Kite Pharma for the treatment of a deadly form of blood cancer. Here are the 8 interesting facts that you should know about the FDA approved, second “living therapy.” Continue reading...

NEW DRUG APPROVAL

FDA Approves Gilead’s Three-Drug Combo Biktarvy® for HIV Treatment

Gilead Sciences’ once-daily single tablet regimen (STR), Biktarvy® received the US FDA approval for the treatment of HIV-1 infection in adults.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.

MARKET INSIGHTS

9 Most Valuable Drugs Under Development (2018)

The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..